Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #44 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Viyash Scientific Limited (this stock) | 10,008 | 161.3 | 4.9% | 13.2% | — | 65 | 27 | 28 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 946 | 112 | 79 | ₹ |
| March 31, 2026 | 920 | 125 | 66 | ₹ |
| Dec. 31, 2025 | 858 | 73 | 49 | ₹ |
| Sept. 30, 2025 | 424 | 27 | 20 | ₹ |
| June 30, 2025 | 441 | 26 | 18 | ₹ |
| March 31, 2025 | 402 | 16 | 10 | ₹ |
| Dec. 31, 2024 | 391 | 8 | 6 | ₹ |
| Sept. 30, 2024 | 369 | 8 | 6 | ₹ |
| June 30, 2024 | 390 | 12 | 9 | ₹ |
| March 31, 2024 | 361 | 3 | 1 | ₹ |
| Dec. 31, 2023 | 329 | 1 | 11 | ₹ |
| Sept. 30, 2023 | 346 | -3 | -7 | ₹ |
| June 30, 2023 | 333 | -56 | -35 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 3,420 | 349 | 225 |
| March 31, 2025 | 1,551 | 44 | 32 |
| March 31, 2024 | 1,370 | -55 | -30 |
| March 31, 2023 | 1,421 | -138 | -122 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 323 | -84 | -123 | 135 | 188 |
| March 31, 2025 | 83 | -25 | -61 | 39 | 44 |
| March 31, 2024 | 31 | -6 | -1 | 31 | -0 |
| March 31, 2023 | 17 | -65 | 32 | 86 | -69 |
| March 31, 2022 | 31 | -94 | 67 | 32 | -2 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 4,628 | 3,115 | 2,824 | 134 | 302 | 2,255 | 946 | 256 | 1,138 | 803 |
| March 31, 2025 | 1,602 | 770 | 654 | 172 | 274 | 873 | 505 | 63 | 232 | 385 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
